GH Research (GHRS) Competitors $12.59 -0.59 (-4.48%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$12.58 0.00 (-0.04%) As of 10/10/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GHRS vs. BEAM, CDTX, CPRX, MLYS, ALVO, BHC, IDYA, BLTE, IBRX, and ARQTShould you be buying GH Research stock or one of its competitors? The main competitors of GH Research include Beam Therapeutics (BEAM), Cidara Therapeutics (CDTX), Catalyst Pharmaceuticals (CPRX), Mineralys Therapeutics (MLYS), Alvotech (ALVO), Bausch Health Cos (BHC), IDEAYA Biosciences (IDYA), Belite Bio (BLTE), ImmunityBio (IBRX), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical products" industry. GH Research vs. Its Competitors Beam Therapeutics Cidara Therapeutics Catalyst Pharmaceuticals Mineralys Therapeutics Alvotech Bausch Health Cos IDEAYA Biosciences Belite Bio ImmunityBio Arcutis Biotherapeutics GH Research (NASDAQ:GHRS) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations. Do analysts prefer GHRS or BEAM? GH Research currently has a consensus price target of $32.00, indicating a potential upside of 154.17%. Beam Therapeutics has a consensus price target of $45.91, indicating a potential upside of 74.43%. Given GH Research's higher probable upside, equities analysts clearly believe GH Research is more favorable than Beam Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GH Research 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67Beam Therapeutics 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 3 Strong Buy rating(s) 2.93 Which has more risk & volatility, GHRS or BEAM? GH Research has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500. Do insiders & institutionals believe in GHRS or BEAM? 56.9% of GH Research shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 41.6% of GH Research shares are owned by insiders. Comparatively, 3.5% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is GHRS or BEAM more profitable? GH Research has a net margin of 0.00% compared to Beam Therapeutics' net margin of -661.31%. GH Research's return on equity of -16.71% beat Beam Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets GH ResearchN/A -16.71% -16.06% Beam Therapeutics -661.31%-43.15%-31.06% Does the media refer more to GHRS or BEAM? In the previous week, Beam Therapeutics had 6 more articles in the media than GH Research. MarketBeat recorded 13 mentions for Beam Therapeutics and 7 mentions for GH Research. GH Research's average media sentiment score of 0.67 beat Beam Therapeutics' score of 0.64 indicating that GH Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation and earnings, GHRS or BEAM? GH Research has higher earnings, but lower revenue than Beam Therapeutics. GH Research is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGH ResearchN/AN/A-$38.96M-$0.74-17.01Beam Therapeutics$63.52M41.92-$376.74M-$4.50-5.85 SummaryGH Research and Beam Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get GH Research News Delivered to You Automatically Sign up to receive the latest news and ratings for GHRS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GHRS vs. The Competition Export to ExcelMetricGH ResearchMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$685.73M$3.38B$6.10B$10.63BDividend YieldN/A2.29%5.67%4.71%P/E Ratio-17.0121.9785.2726.57Price / SalesN/A462.21612.78132.63Price / CashN/A47.2238.5062.09Price / Book3.6610.2112.726.53Net Income-$38.96M-$52.40M$3.30B$275.96M7 Day Performance-3.89%0.88%0.90%-0.77%1 Month Performance0.88%10.41%6.30%3.67%1 Year Performance83.26%27.28%80.41%37.30% GH Research Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GHRSGH Research2.9743 of 5 stars$12.59-4.5%$32.00+154.2%+72.7%$685.73MN/A-17.0110News CoverageAnalyst ForecastBEAMBeam Therapeutics3.0852 of 5 stars$25.89+0.5%$46.40+79.2%+14.3%$2.60B$63.52M-5.75510News CoverageAnalyst ForecastGap UpCDTXCidara Therapeutics4.0479 of 5 stars$96.45-5.4%$122.29+26.8%+974.6%$2.59BN/A-8.6790Trending NewsAnalyst ForecastGap UpCPRXCatalyst Pharmaceuticals4.7742 of 5 stars$20.73-0.5%$33.20+60.2%+2.3%$2.55B$558.50M12.5680Analyst ForecastBuyback AnnouncementMLYSMineralys Therapeutics1.7746 of 5 stars$38.01-0.1%$43.50+14.4%+214.2%$2.52BN/A-10.6828Analyst ForecastALVOAlvotech3.306 of 5 stars$8.58+3.1%$14.00+63.2%-35.9%$2.51B$491.98M37.301,032Analyst ForecastBHCBausch Health Cos4.5504 of 5 stars$6.48-3.0%$9.00+38.9%-24.8%$2.47B$9.63B24.9220,700News CoverageAnalyst ForecastIDYAIDEAYA Biosciences4.0719 of 5 stars$27.49-0.5%$43.36+57.7%-13.1%$2.42B$7M-7.2580Analyst ForecastBLTEBelite Bio2.2924 of 5 stars$78.10+3.3%$96.00+22.9%+43.1%$2.41BN/A-50.3910Analyst ForecastIBRXImmunityBio2.6655 of 5 stars$2.53-0.4%$10.75+324.9%-26.9%$2.40B$14.74M-5.27590ARQTArcutis Biotherapeutics1.3036 of 5 stars$19.76-0.8%$19.80+0.2%+105.0%$2.39B$196.54M-26.35150 Related Companies and Tools Related Companies Beam Therapeutics Alternatives Cidara Therapeutics Alternatives Catalyst Pharmaceuticals Alternatives Mineralys Therapeutics Alternatives Alvotech Alternatives Bausch Health Cos Alternatives IDEAYA Biosciences Alternatives Belite Bio Alternatives ImmunityBio Alternatives Arcutis Biotherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GHRS) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GH Research PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share GH Research With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
